Ondine Biomedical shares jump 14% after positive phase 3 results
AI Summary- Ondine Biomedical reported positive phase 3 results for its nasal photodisinfection technology.
- Shares rose 14% after infections fell an estimated 40% versus standard care.
- The LANTERN study involved more than 5,000 patients.